His week begins with blood. Every Monday, Dr. Siddhartha Mukherjee arrives early at his Columbia University lab to stare through the microscope at slides of red. Waiting very much in Shakespearean fashion for his patient's blood to speak to him.
We speak on a Thursday. Mukherjee is in his loft in New York, making a sandwich and promoting his new book The Song of The Cell: An Exploration of Medicine and The New Human. It is his fourth book, the earlier ones being The Emperor of All Maladies: A Biography of Cancer (which won him a Pulitzer), The Laws of Medicine: Field Notes from an Uncertain Science and The Gene: An Intimate History. Its arrival in stores is very much a worldwide publishing event.
The next two months are big for Mukherjee, for his various identities of oncologist, scientist, writer, and now entrepreneur. Book aside, in December, he flies to Bengaluru to assess the results of a CAR (chimeric antigen receptor) T cell trial for cancer. His laboratory, which has a reputation for cancer research, is responsible for starting one of India's first clinical trials of T-cell therapy.
AT cell is a kind of white blood cell. "A CAR T cell is a T cell that has been weaponised against cancer," he says. "It is a process that can be highly effective in curing patients, but it is also very dangerous."
Immuneel Therapeutics, the Bengaluru-based company that Mukherjee and Biocon chief Kiran Mazumdar Shaw started, is working towards a treatment that will cost far less than treatments in the US. It has recently raised $15 million. IIT Bombay and Tata Memorial are also doing similar trials; theirs is in phase one, and Immuneel is in phase two.
Bu hikaye THE WEEK India dergisinin November 06, 2022 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye THE WEEK India dergisinin November 06, 2022 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Giriş Yap
Indira's Bang
How Indira Gandhi secured the borders, ended food import, before going for the test
Who's Afraid Of A New Nuclear Doctrine?
It has been 50 years since Pokhran I. With its capabilities increasing and global power equations changing, does India need to look at reviewing its nuclear doctrine?
I don't think things will change because of the win
When independent filmmaker Payal Kapadia’s All We Imagine As Light scripted history by winning the Grand Prix at the 77th Cannes Film Festival, it was not just a proud moment for the film's team, but also a triumph for the collective aspirations of women across the country.
Sid for kids
As a child, Sidhartha Mallya wished he had someone in his life to tell him what he wants to convey in his latest children's book, Sad Glad
Ready to roll
Following the Pokhran tests, India has operationalised a credible deterrent that the nation should be proud of
Breaking nuclear apartheid
How India protected its ability to move ahead with the nuclear weapons programme despite not signing the NPT
Power point
The Pokhran tests launched India's march towards being a full partner and participant in the global nuclear order
Shock and awe
India’s comprehensive capability in the nuclear domain is the result of its autonomous pursuit of the atomic programme against all odds
Spied on none, stole from none
A senior scientist during the Pokhran test in 1974 and chairman of the Atomic Energy Commission during the tests in 1998, Dr Rajagopala Chidambaram has been a key figure in the Indian nuclear journey.
Leader with a difference
ARVIND KEJRIWAL'S RETURN TO JAIL APPEARS IMMINENT. BUT HIS BLISTERING POLL CAMPAIGN MAY HAVE BRIGHTENED INDIA BLOC’S PROSPECTS
